{"filing":{"accession_number":"0001193125-26-264514","cik":"0001341235","ticker":"ALDX","company_name":"Aldeyra Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"aldx-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526264514/aldx-20260609.htm"},"events":[{"id":5944,"run_id":5216,"accession_number":"0001193125-26-264514","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.96,"summary":"Darlene Deptula-Hicks was appointed as a Class III director and Chair of the Audit Committee following the 2026 Annual Meeting of Shareholders held on June 9, 2026. The appointment was disclosed via press release and includes compensatory arrangements consisting of stock options and annual fees.","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5691,"accession_number":"0001193125-26-264514","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Darlene Deptula-Hicks as a Class III director and Chair of the Audit Committee following the 2026 annual meeting. While the disclosure includes compensatory details (stock options and annual fees), the principal action is her appointment to the Board and a key committee role, making exec_appointment the most salient classification. Board composition changes are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5693,"accession_number":"0001193125-26-264514","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ms. Deptula-Hicks to the Board of Directors via press release issued on June 9, 2026. Board appointments are material events affecting the composition and governance of the registrant and would influence a reasonable investor's assessment of the company's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5945,"run_id":5216,"accession_number":"0001193125-26-264514","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Shareholders voted at the 2026 Annual Meeting on June 9, 2026, approving three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). Vote counts, abstentions, and broker non-votes were disclosed for each proposal.","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5692,"accession_number":"0001193125-26-264514","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 9, 2026. The filing reports voting outcomes for three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). The disclosure includes vote counts, abstentions, and broker non-votes for each proposal, which is the standard format for shareholder meeting results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5691,"accession_number":"0001193125-26-264514","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Darlene Deptula-Hicks as a Class III director and Chair of the Audit Committee following the 2026 annual meeting. While the disclosure includes compensatory details (stock options and annual fees), the principal action is her appointment to the Board and a key committee role, making exec_appointment the most salient classification. Board composition changes are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-06-09"},{"id":5692,"accession_number":"0001193125-26-264514","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on June 9, 2026. The filing reports voting outcomes for three proposals: election of director Todd C. Brady, M.D., Ph.D. (23,026,101 votes for); ratification of BDO USA, P.C. as independent auditor (43,693,772 votes for); and advisory approval of named executive officer compensation (19,477,504 votes for). The disclosure includes vote counts, abstentions, and broker non-votes for each proposal, which is the standard format for shareholder meeting results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-06-09"},{"id":5693,"accession_number":"0001193125-26-264514","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ms. Deptula-Hicks to the Board of Directors via press release issued on June 9, 2026. Board appointments are material events affecting the composition and governance of the registrant and would influence a reasonable investor's assessment of the company's leadership and oversight structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T10:04:16.372513+00:00","company_name":"Aldeyra Therapeutics, Inc.","ticker":"ALDX","filing_date":"2026-06-09"}]}